The dichotomy of the Insulin-like growth factor 1 receptor: RTK and GPCR: friend or foe for cancer treatment?

Growth Hormone and IGF Research

Volumn 25, Issue 1, 2015, Pages 2-12

  Crudden, Caitrin ^a   Ilic, Marina ^a   Suleymanova, Naida ^a   Worrall, Claire ^a   Girnita, Ada ^a   Girnita, Leonard ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Beta Arrestin; Biased signalling; Cancer; GPCR; GRK; IGF 1R; RTK; Ubiquitination

Indexed keywords

ANTINEOPLASTIC AGENT; BETA 2 ADRENERGIC RECEPTOR; BETA ARRESTIN; BETA ARRESTIN 1; BETA ARRESTIN 2; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLOLIGNAN PICROPODOPHYLLIN; FIGITUMUMAB; G PROTEIN COUPLED RECEPTOR; GUANINE NUCLEOTIDE EXCHANGE FACTOR; PHOSPHODIESTERASE IV; PROTEIN MDM2; PROTEIN TYROSINE KINASE; SOMATOMEDIN C RECEPTOR; SOMATOMEDIN C RECEPTOR ANTIBODY; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; BINDING AFFINITY; CANCER CHEMOTHERAPY; CARBOXY TERMINAL SEQUENCE; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; ENDOCYTOSIS; ENZYME BINDING; ENZYME PHOSPHORYLATION; EWING SARCOMA; FEEDBACK SYSTEM; LIGAND BINDING; LUNG CARCINOMA; MOUSE; NONHUMAN; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; PROTEIN TRANSPORT; RECEPTOR DOWN REGULATION; REVIEW; SECOND MESSENGER; SIGNAL TRANSDUCTION; UBIQUITINATION; ANIMAL; CLASSIFICATION; HUMAN; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASMS;

ANIMALS; HUMANS; MICE; MOLECULAR TARGETED THERAPY; NEOPLASMS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, IGF TYPE 1; RECEPTORS, G-PROTEIN-COUPLED;

EID: 84920264191     PISSN: 10966374     EISSN: 15322238     Source Type: Journal    
DOI: 10.1016/j.ghir.2014.10.002     Document Type: Review

References (158)

1. Aaronson S.A. Growth factors and cancer. Science 1991, 254:1146-1153.
2. Adams T.E., Epa V.C., Garrett T.P., Ward C.W. Structure and function of the type 1 insulin-like growth factor receptor. Cell. Mol. Life Sci. 2000, 57:1050-1093.
3. Ahlen J., Wejde J., Brosjo O., von Rosen A., Weng W.H., Girnita L., Larsson O., Larsson C. Insulin-like growth factor type 1 receptor expression correlates to good prognosis in highly malignant soft tissue sarcoma. Clin. Cancer Res. 2005, 11:206-216.
4. Ahmed M.R., Zhan X., Song X., Kook S., Gurevich V.V., Gurevich E.V. Ubiquitin ligase parkin promotes Mdm2-arrestin interaction but inhibits arrestin ubiquitination. Biochemistry 2011, 50:3749-3763.
5. Ahn S., Wei H., Garrison T.R., Lefkowitz R.J. Reciprocal regulation of angiotensin receptor-activated extracellular signal-regulated kinases by beta-arrestins 1 and 2. J. Biol. Chem. 2004, 279:7807-7811.
6. All-Ericsson C., Girnita L., Seregard S., Bartolazzi A., Jager M.J., Larsson O. Insulin-like growth factor-1 receptor in uveal melanoma: a predictor for metastatic disease and a potential therapeutic target. Invest. Ophthalmol. Vis. Sci. 2002, 43:1-8.
7. Arteaga C.L. Interference of the IGF system as a strategy to inhibit breast cancer growth. Breast Cancer Res. Treat. 1992, 22:101-106.
8. Bailyes E.M., Nave B.T., Soos M.A., Orr S.R., Hayward A.C., Siddle K. Insulin receptor/IGF-I receptor hybrids are widely distributed in mammalian tissues: quantification of individual receptor species by selective immunoprecipitation and immunoblotting. Biochem. J. 1997, 327(Pt 1):209-215.
9. Baserga R. The insulin-like growth factor-I receptor as a target for cancer therapy. Expert Opin. Ther. Targets 2005, 9:753-768.
10. Baserga R. The decline and fall of the IGF-I receptor. J. Cell. Physiol. 2012, 228:675-679.
11. Baserga R., Peruzzi F., Reiss K. The IGF-1 receptor in cancer biology. Int. J. Cancer 2003, 107:873-877.
12. Beauchamp M.C., Yasmeen A., Knafo A., Gotlieb W.H. Targeting insulin and insulin-like growth factor pathways in epithelial ovarian cancer. J. Oncol. 2010, 2010. (257058).
13. Belfiore A., Frasca F., Pandini G., Sciacca L., Vigneri R. Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease. Endocr. Rev. 2009, 30:586-623.
14. Berger N.A. Obesity and cancer pathogenesis. Ann. N. Y. Acad. Sci. 2014, 1311:57-76.
15. Bohn L.M., Lefkowitz R.J., Gainetdinov R.R., Peppel K., Caron M.G., Lin F.T. Enhanced morphine analgesia in mice lacking beta-arrestin 2. Science 1999, 286:2495-2498.
16. Broussas M., Dupont J., Gonzalez A., Blaecke A., Fournier M., Corvaia N., Goetsch L. Molecular mechanisms involved in activity of h7C10, a humanized monoclonal antibody, to IGF-1 receptor. Int. J. Cancer 2009, 124:2281-2293.
17. Cabrera-Vera T.M., Vanhauwe J., Thomas T.O., Medkova M., Preininger A., Mazzoni M.R., Hamm H.E. Insights into G protein structure, function, and regulation. Endocr. Rev. 2003, 24:765-781.
18. Clemmons D.R. Modifying IGF1 activity: an approach to treat endocrine disorders, atherosclerosis and cancer. Nat. Rev. Drug Discov. 2007, 6:821-833.
19. Coffa S., Breitman M., Hanson S.M., Callaway K., Kook S., Dalby K.N., Gurevich V.V. The effect of arrestin conformation on the recruitment of c-Raf1, MEK1, and ERK1/2 activation. PLoS ONE 2011, 6:e28723.
20. Conner D.A., Mathier M.A., Mortensen R.M., Christe M., Vatner S.F., Seidman C.E., Seidman J.G. beta-Arrestin1 knockout mice appear normal but demonstrate altered cardiac responses to beta-adrenergic stimulation. Circ. Res. 1997, 81:1021-1026.
21. Conti L., Regis G., Longo A., Bernabei P., Chiarle R., Giovarelli M., Novelli F. In the absence of IGF-1 signaling, IFN-gamma suppresses human malignant T-cell growth. Blood 2007, 109:2496-2504.
22. Corral J., Lopez-Villalobos J.L., Gomez-Izquierdo L., Borrego I., Paz-Ares L. Pathologic complete responses after chemotherapy plus figitumumab in stage IV non-small-cell lung cancer. J. Clin. Oncol. 2011, 29:e163-e165.
23. Dalle S., Ricketts W., Imamura T., Vollenweider P., Olefsky J.M. Insulin and insulin-like growth factor I receptors utilize different G protein signaling components. J. Biol. Chem. 2001, 276:15688-15695.
24. De Marco P., Bartella V., Vivacqua A., Lappano R., Santolla M.F., Morcavallo A., Pezzi V., Belfiore A., Maggiolini M. Insulin-like growth factor-I regulates GPER expression and function in cancer cells. Oncogene 2013, 32:678-688.
25. Delcourt N., Bockaert J., Marin P. GPCR-jacking: from a new route in RTK signalling to a new concept in GPCR activation. Trends Pharmacol. Sci. 2007, 28:602-607.
26. DeWire S.M., Ahn S., Lefkowitz R.J., Shenoy S.K. Beta-arrestins and cell signaling. Annu. Rev. Physiol. 2007, 69:483-510.
27. Dong J.Y., Sereno A., Aivazian D., Langley E., Miller B.R., Snyder W.B., Chan E., Cantele M., Morena R., Joseph I., Boccia A., Virata C., Gamez J., Yco G., Favis M., Wu X.F., Graff C.P., Wang Q., Rohde E., Rennard R., Berquist L., Huang F., Zhang Y., Gao S.X., Ho S.N., Demarest S.J., Reff M.E., Hariharan K., Glaser S.M. A stable IgG-like bispecific antibody targeting the epidermal growth factor receptor and the type I insulin-like growth factor receptor demonstrates superior anti-tumor activity. MAbs 2011, 3:273-288.
28. Dunn S.E., Ehrlich M., Sharp N.J., Reiss K., Solomon G., Hawkins R., Baserga R., Barrett J.C. A dominant negative mutant of the insulin-like growth factor-I receptor inhibits the adhesion, invasion, and metastasis of breast cancer. Cancer Res. 1998, 58:3353-3361.
29. Economou M.A., All-Ericsson C., Bykov V., Girnita L., Bartolazzi A., Larsson O., Seregard S. Receptors for the liver synthesized growth factors IGF-1 and HGF/SF in uveal melanoma: intercorrelation and prognostic implications. Invest. Ophthalmol. Vis. Sci. 2005, 46:4372-4375.
30. Economou M.A., Andersson S., Vasilcanu D., All-Ericsson C., Menu E., Girnita A., Girnita L., Axelson M., Seregard S., Larsson O. Oral picropodophyllin (PPP) is well tolerated in vivo and inhibits IGF-1R expression and growth of uveal melanoma. Invest. Ophthalmol. Vis. Sci. 2008, 49:2337-2342.
31. Economou M.A., Wu J., Vasilcanu D., Rosengren L., All-Ericsson C., van der Ploeg I., Menu E., Girnita L., Axelson M., Larsson O., Seregard S., Kvanta A. Inhibition of VEGF secretion and experimental choroidal neovascularization by picropodophyllin (PPP), an inhibitor of the insulin-like growth factor-1 receptor. Invest. Ophthalmol. Vis. Sci. 2008, 49:2620-2626.
32. Evdokimova V., Tognon C.E., Benatar T., Yang W., Krutikov K., Pollak M., Sorensen P.H., Seth A. IGFBP7 binds to the IGF-1 receptor and blocks its activation by insulin-like growth factors. Sci. Signal. 2012, 5:ra92.
33. Furukawa J., Wraight C.J., Freier S.M., Peralta E., Atley L.M., Monia B.P., Gleave M.E., Cox M.E. Antisense oligonucleotide targeting of insulin-like growth factor-1 receptor (IGF-1R) in prostate cancer. Prostate 2010, 70:206-218.
34. Gallagher E.J., LeRoith D. Minireview: IGF, Insulin, and Cancer. Endocrinology 2011, 152:2546-2551.
35. Gasbarri A., Del Prete F., Girnita L., Martegani M.P., Natali P.G., Bartolazzi A. CD44s adhesive function spontaneous and PMA-inducible CD44 cleavage are regulated at post-translational level in cells of melanocytic lineage. Melanoma Res. 2003, 13:325-337.
36. Gesty-Palmer D., Chen M., Reiter E., Ahn S., Nelson C.D., Wang S., Eckhardt A.E., Cowan C.L., Spurney R.F., Luttrell L.M., Lefkowitz R.J. Distinct beta-arrestin- and G protein-dependent pathways for parathyroid hormone receptor-stimulated ERK1/2 activation. J. Biol. Chem. 2006, 281:10856-10864.
37. Girnita A., All-Ericsson C., Economou M.A., Astrom K., Axelson M., Seregard S., Larsson O., Girnita L. The insulin-like growth factor-I receptor inhibitor picropodophyllin causes tumor regression and attenuates mechanisms involved in invasion of uveal melanoma cells. Clin. Cancer Res. 2006, 12:1383-1391.
38. Girnita A., Girnita L., del Prete F., Bartolazzi A., Larsson O., Axelson M. Cyclolignans as inhibitors of the insulin-like growth factor-1 receptor and malignant cell growth. Cancer Res. 2004, 64:236-242.
39. Girnita A., Zheng H., Gronberg A., Girnita L., Stahle M. Identification of the cathelicidin peptide LL-37 as agonist for the type I insulin-like growth factor receptor. Oncogene 2011, 31:352-365.
40. Girnita L., Girnita A., Brodin B., Xie Y., Nilsson G., Dricu A., Lundeberg J., Wejde J., Bartolazzi A., Wiman K.G., Larsson O. Increased expression of insulin-like growth factor I receptor in malignant cells expressing aberrant p53: functional impact. Cancer Res. 2000, 60:5278-5283.
41. Girnita L., Girnita A., Larsson O. Mdm2-dependent ubiquitination and degradation of the insulin-like growth factor 1 receptor. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:8247-8252.
42. Girnita L., Girnita A., Wang M., Meis-Kindblom J.M., Kindblom L.G., Larsson O. A link between basic fibroblast growth factor (bFGF) and EWS/FLI-1 in Ewing's sarcoma cells. Oncogene 2000, 19:4298-4301.
43. Girnita L., Shenoy S.K., Sehat B., Vasilcanu R., Girnita A., Lefkowitz R.J., Larsson O. {beta}-Arrestin is crucial for ubiquitination and down-regulation of the insulin-like growth factor-1 receptor by acting as adaptor for the MDM2 E3 ligase. J. Biol. Chem. 2005, 280:24412-24419.
44. Girnita L., Shenoy S.K., Sehat B., Vasilcanu R., Vasilcanu D., Girnita A., Lefkowitz R.J., Larsson O. Beta-arrestin and Mdm2 mediate IGF-1 receptor-stimulated ERK activation and cell cycle progression. J. Biol. Chem. 2007, 282:11329-11338.
45. Girnita L., Wang M., Xie Y., Nilsson G., Dricu A., Wejde J., Larsson O. Inhibition of N-linked glycosylation down-regulates insulin-like growth factor-1 receptor at the cell surface and kills Ewing's sarcoma cells: therapeutic implications. Anticancer Drug Des. 2000, 15:67-72.
46. Girnita L., Sahlin S., Orrego A., Seregard S. Malignant solitary fibrous tumour of the orbit. Acta Ophthalmol. 2009, 87:464-467.
47. Girnita L., Worrall C., Takahashi S.I., Seregard S., Girnita A. Something old, something new and something borrowed: emerging paradigm of insulin-like growth factor type 1 receptor (IGF-1R) signaling regulation. Cell. Mol. Life Sci. 2014, 71:2403-2427.
48. Gualberto A., Dolled-Filhart M., Gustavson M., Christiansen J., Wang Y.F., Hixon M.L., Reynolds J., McDonald S., Ang A., Rimm D.L., Langer C.J., Blakely J., Garland L., Paz-Ares L.G., Karp D.D., Lee A.V. Molecular analysis of non-small cell lung cancer identifies subsets with different sensitivity to insulin-like growth factor I receptor inhibition. Clin. Cancer Res. 2010, 16:4654-4665.
49. Gualberto A., Pollak M. Clinical development of inhibitors of the insulin-like growth factor receptor in oncology. Curr. Drug Targets 2009, 10:923-936.
50. Gualberto A., Pollak M. Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions. Oncogene 2009, 28:3009-3021.
51. Gurevich E.V., Tesmer J.J., Mushegian A., Gurevich V.V. G protein-coupled receptor kinases: more than just kinases and not only for GPCRs. Pharmacol. Ther. 2012, 133:40-69.
52. Hallak H., Seiler A.E., Green J.S., Ross B.N., Rubin R. Association of heterotrimeric G(i) with the insulin-like growth factor-I receptor. Release of G(betagamma) subunits upon receptor activation. J. Biol. Chem. 2000, 275:2255-2258.
53. Hara M.R., Kovacs J.J., Whalen E.J., Rajagopal S., Strachan R.T., Grant W., Towers A.J., Williams B., Lam C.M., Xiao K., Shenoy S.K., Gregory S.G., Ahn S., Duckett D.R., Lefkowitz R.J. A stress response pathway regulates DNA damage through beta2-adrenoreceptors and beta-arrestin-1. Nature 2011, 477:349-353.
54. Hashemi J., Worrall C., Vasilcanu D., Fryknas M., Sulaiman L., Karimi M., Weng W.H., Lui W.O., Rudduck C., Axelson M., Jernberg-Wiklund H., Girnita L., Larsson O., Larsson C. Molecular characterization of acquired tolerance of tumor cells to picropodophyllin (PPP). PLoS ONE 2011, 6:e14757.
55. Heldin C.H. Dimerization of cell surface receptors in signal transduction. Cell 1995, 80:213-223.
56. Heyworth C.M., Grey A.M., Wilson S.R., Hanski E., Houslay M.D. The action of islet activating protein (pertussis toxin) on insulin's ability to inhibit adenylate cyclase and activate cyclic AMP phosphodiesterases in hepatocytes. Biochem. J. 1986, 235:145-149.
57. Hupfeld C.J., Olefsky J.M. Regulation of receptor tyrosine kinase signaling by GRKs and beta-arrestins. Annu. Rev. Physiol. 2007, 69:561-577.
58. Jaber M., Koch W.J., Rockman H., Smith B., Bond R.A., Sulik K.K., Ross J., Lefkowitz R.J., Caron M.G., Giros B. Essential role of beta-adrenergic receptor kinase 1 in cardiac development and function. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:12974-12979.
59. Jernberg-Wiklund H., Nilsson K. Control of apoptosis in human multiple myeloma by insulin-like growth factor I (IGF-I). Adv. Cancer Res. 2007, 97:139-165.
60. Jones J.I., Clemmons D.R. Insulin-like growth factors and their binding proteins: biological actions. Endocr. Rev. 1995, 16:3-34.
61. Juergens H., Daw N.C., Geoerger B., Ferrari S., Villarroel M., Aerts I., Whelan J., Dirksen U., Hixon M.L., Yin D., Wang T., Green S., Paccagnella L., Gualberto A. Preliminary efficacy of the anti-insulin-like growth factor type 1 receptor antibody figitumumab in patients with refractory Ewing sarcoma. J. Clin. Oncol. 2011, 29:4534-4540.
62. Kahsai A.W., Xiao K., Rajagopal S., Ahn S., Shukla A.K., Sun J., Oas T.G., Lefkowitz R.J. Multiple ligand-specific conformations of the β2-adrenergic receptor. Nat. Chem. Biol. 2011, 7:692-700.
63. Kalebic T., Tsokos M., Helman L.J. In vivo treatment with antibody against IGF-1 receptor suppresses growth of human rhabdomyosarcoma and down-regulates p34cdc2. Cancer Res. 1994, 54:5531-5534.
64. Kanter-Lewensohn L., Dricu A., Girnita L., Wejde J., Larsson O. Expression of insulin-like growth factor-1 receptor (IGF-1R) and p27Kip1 in melanocytic tumors: a potential regulatory role of IGF-1 pathway in distribution of p27Kip1 between different cyclins. Growth Factors 2000, 17:193-202.
65. Kanter-Lewensohn L., Girnita L., Girnita A., Dricu A., Olsson G., Leech L., Nilsson G., Hilding A., Wejde J., Brismar K., Larsson O. Tamoxifen-induced cell death in malignant melanoma cells: possible involvement of the insulin-like growth factor-1 (IGF-1) pathway. Mol. Cell. Endocrinol. 2000, 165:131-137.
66. Kenakin T. Functional selectivity and biased receptor signaling. J. Pharmacol. Exp. Ther. 2011, 336:296-302.
67. Kim Y.M., Benovic J.L. Differential roles of arrestin-2 interaction with clathrin and adaptor protein 2 in G protein-coupled receptor trafficking. J. Biol. Chem. 2002, 277:30760-30768.
68. Klinakis A., Szabolcs M., Chen G., Xuan S., Hibshoosh H., Efstratiadis A. Igf1r as a therapeutic target in a mouse model of basal-like breast cancer. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:2359-2364.
69. Kohout T.A., Lefkowitz R.J. Regulation of G protein-coupled receptor kinases and arrestins during receptor desensitization. Mol. Pharmacol. 2003, 63:9-18.
70. Laporte S.A., Miller W.E., Kim K.M., Caron M.G. beta-Arrestin/AP-2 interaction in G protein-coupled receptor internalization: identification of a beta-arrestin binging site in beta 2-adaptin. J. Biol. Chem. 2002, 277:9247-9254.
71. Lappano R., Maggiolini M. G protein-coupled receptors: novel targets for drug discovery in cancer. Nat. Rev. Drug Discov. 2011, 10:47-60.
72. Lefkowitz R.J. Historical review: a brief history and personal retrospective of seven-transmembrane receptors. Trends Pharmacol. Sci. 2004, 25:413-422.
73. Lefkowitz R.J. Arrestins come of age: a personal historical perspective. Prog. Mol. Biol. Transl. Sci. 2013, 118:3-18.
74. Lefkowitz R.J., Shenoy S.K. Transduction of receptor signals by beta-arrestins. Science 2005, 308:512-517.
75. Lefkowitz R.J., Whalen E.J. Beta-Arrestins: Traffic Cops of Cell Signaling. Curr. Opin. Cell Biol. 2004, 16:162-168.
76. Lefkowitz R.J., Rajagopal K., Whalen E.J. New roles for beta-arrestins in cell signalling: not just for seven-transmembrance receptors. Mol. Cell. 2006, 24:643-652.
77. LeRoith D., Roberts C.T. The insulin-like growth factor system and cancer. Cancer Lett. 2003, 195:127-137.
78. Liggett S.B. Phosphorylation barcoding as a mechanism of directing GPCR signaling. Sci. Signal. 2011, 4:e36.
79. Lin F.T., Daaka Y., Lefkowitz R.J. beta-arrestins regulate mitogenic signaling and clathrin-mediated endocytosis of the insulin-like growth factor I receptor. J. Biol. Chem. 1998, 273:31640-31643.
80. Lin F.T., Krueger K.M., Kendall H.E., Daaka Y., Fredericks Z.L., Pitcher J.A., Lefkowitz R.J. Clathrin-mediated endocytosis of the beta-adrenergic receptor is regulated by phosphorylation/dephosphorylation of beta-arrestin1. J. Biol. Chem. 1997, 272:31051-31057.
81. Long L., Rubin R., Baserga R., Brodt P. Loss of the metastatic phenotype in murine carcinoma cells expressing an antisense RNA to the insulin-like growth factor receptor. Cancer Res. 1995, 55:1006-1009.
82. Luttrell L., Kilgour E., Larner J., Romero G. A pertussis toxin-sensitive G-protein mediates some aspects of insulin action in BC3H-1 murine myocytes. J. Biol. Chem. 1990, 265:16873-16879.
83. Luttrell L.M., Daaka Y., Lefkowitz R.J. Regulation of tyrosine kinase cascades by G-protein-coupled receptors. Curr. Opin. Cell Biol. 1999, 11:177-183.
84. Luttrell L.M., Gesty-Palmer D. Beyond desensitization: physiological relevance of arrestin-dependent signaling. Pharmacol. Rev. 2010, 62:305-330.
85. Luttrell L.M., van Biesen T., Hawes B.E., Koch W.J., Touhara K., Lefkowitz R.J. G beta gamma subunits mediate mitogen-activated protein kinase activation by the tyrosine kinase insulin-like growth factor 1 receptor. J. Biol. Chem. 1995, 270:16495-16498.
86. Ma L., Pei G. Beta-arrestin signaling and regulation of transcription. J. Cell Sci. 2007, 120:213-218.
87. Mayor F., Lucas E., Jurado-Pueyo M., Garcia-Guerra L., Nieto-Vazquez I., Vila-Bedmar R., Fernandez-Veledo S., Murga C. G Protein-coupled receptor kinase 2 (GRK2): A novel modulator of insulin resistance. Arch. Physiol. Biochem. 2011, 117:125-130.
88. McDonald P.H., Lefkowitz R.J. Beta-Arrestins: new roles in regulating heptahelical receptors' functions. Cell. Signal. 2001, 13:683-689.
89. Menu E., Jernberg-Wiklund H., Stromberg T., De Raeve H., Girnita L., Larsson O., Axelson M., Asosingh K., Nilsson K., Van Camp B., Vanderkerken K. Inhibiting the IGF-1 receptor tyrosine kinase with the cyclolignan PPP: an in vitro and in vivo study in the 5T33MM mouse model. Blood 2006, 107:655-660.
90. Mushegian A., Gurevich V.V., Gurevich E.V. The origin and evolution of G protein-coupled receptor kinases. PLoS ONE 2012, 7:e33806.
91. Nakae J., Kido Y., Accili D. Distinct and overlapping functions of insulin and IGF-I receptors. Endocr. Rev. 2001, 22:818-835.
92. Natalishvili N., Axelson M., Girnita L., Larsson O., Vasilcanu D. Aberrant intracellular IGF-1R beta-subunit makes receptor knockout cells (IGF1R-/-) susceptible to oncogenic transformation. Exp. Cell Res. 2009, 315:1458-1467.
93. Nelson C.D., Perry S.J., Regier D.S., Prescott S.M., Topham M.K., Lefkowitz R.J. Targeting of diacylglycerol degradation to M1 muscarinic receptors by beta-arrestins. Science 2007, 315:663-666.
94. Nussbaum T., Samarin J., Ehemann V., Bissinger M., Ryschich E., Khamidjanov A., Yu X., Gretz N., Schirmacher P., Breuhahn K. Autocrine insulin-like growth factor-II stimulation of tumor cell migration is a progression step in human hepatocarcinogenesis. Hepatology 2008, 48:146-156.
95. O'Hayre M., Degese M.S., Gutkind J.S. Novel insights into G protein and G protein-coupled receptor signaling in cancer. Curr. Opin. Cell Biol. 2014, 27:126-135.
96. Oakley R.H., Laporte S.A., Holt J.A., Barak L.S., Caron M.G. Association of beta-arrestin with G protein-coupled receptors during clathrin-mediated endocytosis dictates the profile of receptor resensitization. J. Biol. Chem. 1999, 274:32248-32257.
97. Oakley R.H., Laporte S.A., Holt J.A., Barak L.S., Caron M.G. Molecular determinants underlying the formation of stable intracellular G protein-coupled receptor-beta-arrestin complexes after receptor endocytosis*. J. Biol. Chem. 2001, 276:19452-19460.
98. Oakley R.H., Laporte S.A., Holt J.A., Caron M.G., Barak L.S. Differential affinities of visual arrestin, beta arrestin1, and beta arrestin2 for G protein-coupled receptors delineate two major classes of receptors. J. Biol. Chem. 2000, 275:17201-17210.
99. Olmos D., Martins A.S., Jones R.L., Alam S., Scurr M., Judson I.R. Targeting the insulin-like growth factor 1 receptor in Ewing's sarcoma: reality and expectations. Sarcoma 2011, 2011:402508.
100. Olmos D., Postel-Vinay S., Molife L.R., Okuno S.H., Schuetze S.M., Paccagnella M.L., Batzel G.N., Yin D., Pritchard-Jones K., Judson I., Worden F.P., Gualberto A., Scurr M., de Bono J.S., Haluska P. Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study. Lancet Oncol. 2009, 11:129-135.
101. Pearce L.R., Komander D., Alessi D.R. The nuts and bolts of AGC protein kinases. Nat. Rev. Mol. Cell Biol. 2010, 11:9-22.
102. Penela P., Ribas C., Mayor F. Mechanisms of regulation of the expression and function of G protein-coupled receptor kinases. Cell. Signal. 2003, 15:973-981.
103. Perry S.J., Baillie G.S., Kohout T.A., McPhee I., Magiera M.M., Ang K.L., Miller W.E., McLean A.J., Conti M., Houslay M.D., Lefkowitz R.J. Targeting of cyclic AMP degradation to beta 2-adrenergic receptors by beta-arrestins. Science 2002, 298:834-836.
104. Petrenko A.G., Zozulya S.A., Deyev I.E., Eladari D. Insulin receptor-related receptor as an extracellular pH sensor involved in the regulation of acid-base balance. Biochim. Biophys. Acta 2012, 1834:2170-2175.
105. Pitcher J.A., Tesmer J.J., Freeman J.L., Capel W.D., Stone W.C., Lefkowitz R.J. Feedback inhibition of G protein-coupled receptor kinase 2 (GRK2) activity by extracellular signal-regulated kinases. J. Biol. Chem. 1999, 274:34531-34534.
106. Pollak M. The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat. Rev. Cancer 2012, 12:159-169.
107. Povsic T.J., Kohout T.A., Lefkowitz R.J. Beta-arrestin1 mediates insulin-like growth factor 1 (IGF-1) activation of phosphatidylinositol 3-kinase (PI3K) and anti-apoptosis. J. Biol. Chem. 2003, 278:51334-51339.
108. Pyne N.J., Pyne S. Receptor tyrosine kinase-G-protein-coupled receptor signalling platforms: out of the shadow?. Trends Pharmacol. Sci. 2011, 32:443-450.
109. Rajagopal S., Rajagopal K., Lefkowitz R.J. Teaching old receptors new tricks: biasing seven-transmembrane receptors. Nat. Rev. Drug Discov. 2010, 9:373-386.
110. Razuvaev A., Henderson B., Girnita L., Larsson O., Axelson M., Hedin U., Roy J. The cyclolignan picropodophyllin attenuates intimal hyperplasia after rat carotid balloon injury by blocking insulin-like growth factor-1 receptor signaling. J. Vasc. Surg. 2007, 46:108-115.
111. Reiss K., D'Ambrosio C., Tu X., Tu C., Baserga R. Inhibition of tumor growth by a dominant negative mutant of the insulin-like growth factor I receptor with a bystander effect. Clin. Cancer Res. 1998, 4:2647-2655.
112. Reiter E., Ahn S., Shukla A.K., Lefkowitz R.J. Molecular mechanism of β-arrestin-biased agonism at seven-transmembrane receptors. Annu. Rev. Pharmacol. Toxicol. 2012, 52:179-197.
113. Reiter E., Lefkowitz R.J. GRKs and beta-arrestins: roles in receptor silencing, trafficking and signaling. Trends Endocrinol. Metab. 2006, 17:159-165.
114. Resnicoff M., Coppola D., Sell C., Rubin R., Ferrone S., Baserga R. Growth inhibition of human melanoma cells in nude mice by antisense strategies to the type 1 insulin-like growth factor receptor. Cancer Res. 1994, 54:4848-4850.
115. Resnicoff M., Sell C., Rubini M., Coppola D., Ambrose D., Baserga R., Rubin R. Rat glioblastoma cells expressing an antisense RNA to the insulin-like growth factor-1 (IGF-1) receptor are nontumorigenic and induce regression of wild-type tumors. Cancer Res. 1994, 54:2218-2222.
116. Rosengren L., Vasilcanu D., Vasilcanu R., Fickenscher S., Sehat B., Natalishvili N., Naughton S., Yin S., Girnita A., Girnita L., Axelson M., Larsson O. IGF-1R tyrosine kinase expression and dependency in clones of IGF-1R knockout cells (R-). Biochem. Biophys. Res. Commun. 2006, 347:1059-1066.
117. Rothenberg P.L., Kahn C.R. Insulin inhibits pertussis toxin-catalyzed ADP-ribosylation of G-proteins. Evidence for a novel interaction between insulin receptors and G-proteins. J. Biol. Chem. 1988, 263:15546-15552.
118. Rowinsky E.K., Youssoufian H., Burtrum D., Ludwig D.L. IMC-A12, a human IgG, monoclonal antibody to the insulin-like growth factor I receptor. Clin. Cancer Res. 2007, 13:5549S-5555S.
119. Runnels H.A., Arbuckle J.A., Bailey K.S., Nicastro P.J., Sun D., Pegg J.A., Meyer D.M., Evans M., Bono C.P., Lie W.R., Moffat M.A., Casperson G.F., Lennard S., Elvin J., Vaughan T., Smith C.E., Morton P.A. Human Monoclonal Antibodies to the Insulin-like Growth Factor 1 Receptor Inhibit Receptor Activation and Tumor Growth in Preclinical Studies. Adv. Ther. 2010, 27:458-475.
120. Scartozzi M., Bianconi M., Maccaroni E., Giampieri R., Del Prete M., Berardi R., Cascinu S. State of the art and future perspectives for the use of insulin-like growth factor receptor 1 (IGF-1R) targeted treatment strategies in solid tumors. Discov. Med. 2011, 11:144-153.
121. Sehat B., Andersson S., Girnita L., Larsson O. Identification of c-Cbl as a new ligase for insulin-like growth factor-I receptor with distinct roles from Mdm2 in receptor ubiquitination and endocytosis. Cancer Res. 2008, 68:5669-5677.
122. Sehat B., Andersson S., Vasilcanu R., Girnita L., Larsson O. Role of ubiquitination in IGF-1 receptor signaling and degradation. PLoS ONE 2007, 2:e340.
123. Shapiro D.N., Jones B.G., Shapiro L.H., Dias P., Houghton P.J. Antisense-mediated reduction in insulin-like growth factor-I receptor expression suppresses the malignant phenotype of a human alveolar rhabdomyosarcoma. J. Clin. Invest. 1994, 94:1235-1242.
124. Shenoy S.K., Drake M.T., Nelson C.D., Houtz D.A., Xiao K., Madabushi S., Reiter E., Premont R.T., Lichtarge O., Lefkowitz R.J. beta-arrestin-dependent, G protein-independent ERK1/2 activation by the beta2 adrenergic receptor. J. Biol. Chem. 2006, 281:1261-1273.
125. Shenoy S.K., Lefkowitz R.J. Beta-arrestin-mediated receptor trafficking and signal transduction. Trends Pharmacol. Sci. 2011, 32:521-533.
126. Shenoy S.K., Lefkowitz R.J. Multifaceted roles of beta-arrestins in the regulation of seven-membrane-spanning receptor trafficking and signalling. Biochem. J. 2003, 375:503-515.
127. Shenoy S.K., Lefkowitz R.J. Trafficking patterns of beta-arrestin and G protein-coupled receptors determined by the kinetics of beta-arrestin deubiquitination. J. Biol. Chem. 2003, 278:14498-14506.
128. Shenoy S.K., McDonald P.H., Kohout T.A., Lefkowitz R.J. Regulation of receptor fate by ubiquitination of activated beta 2-adrenergic receptor and beta-arrestin. Science 2001, 294:1307-1313.
129. Shetzline M.A., Walker J.K., Valenzano K.J., Premont R.T. Vasoactive intestinal polypeptide type-1 receptor regulation. Desensitization, phosphorylation, and sequestration. J. Biol. Chem. 2002, 277:25519-25526.
130. Shukla A.K., Xiao K., Lefkowitz R.J. Emerging paradigms of beta-arrestin-dependent seven transmembrane receptor signaling. Trends Biochem. Sci. 2011, 36:457-469.
131. Simmons M.A. Functional selectivity, ligand-directed trafficking, conformation-specific agonism: what's in a name?. Mol. Interv. 2005, 5:154-157.
132. Song X., Raman D., Gurevich E.V., Vishnivetskiy S.A., Gurevich V.V. Visual and both non-visual arrestins in their "inactive" conformation bind JNK3 and Mdm2 and relocalize them from the nucleus to the cytoplasm. J. Biol. Chem. 2006, 281:21491-21499.
133. Stephenson R.P. A modification of receptor theory. Br. J. Pharmacol. Chemother. 1956, 11:379-393.
134. Stromberg T., Ekman S., Girnita L., Dimberg L.Y., Larsson O., Axelson M., Lennartsson J., Hellman U., Carlson K., Osterborg A., Vanderkerken K., Nilsson K., Jernberg-Wiklund H. IGF-1 receptor tyrosine kinase inhibition by the cyclolignan PPP induces G2/M-phase accumulation and apoptosis in multiple myeloma cells. Blood 2006, 107:669-678.
135. Strous G.J., Schantl J.A. Beta-arrestin and Mdm2, unsuspected partners in signaling from the cell surface. Sci. STKE 2001, 2001:e41.
136. Tohgo A., Choy E.W., Gesty-Palmer D., Pierce K.L., Laporte S., Oakley R.H., Caron M.G., Lefkowitz R.J., Luttrell L.M. The stability of the G protein-coupled receptor-beta-arrestin interaction determines the mechanism and functional consequence of ERK activation. J. Biol. Chem. 2003, 278:6258-6267.
137. Tohgo A., Pierce K.L., Choy E.W., Lefkowitz R.J., Luttrell L.M. beta-Arrestin scaffolding of the ERK cascade enhances cytosolic ERK activity but inhibits ERK-mediated transcription following angiotensin AT1a receptor stimulation. J. Biol. Chem. 2002, 277:9429-9436.
138. Tornkvist M., Natalishvili N., Xie Y., Girnita A., D'Arcy P., Brodin B., Axelson M., Girnita L. Differential roles of SS18-SSX fusion gene and insulin-like growth factor-1 receptor in synovial sarcoma cell growth. Biochem. Biophys. Res. Commun. 2008, 368:793-800.
139. Trojan J., Blossey B.K., Johnson T.R., Rudin S.D., Tykocinski M., Ilan J. Loss of tumorigenicity of rat glioblastoma directed by episome-based antisense cDNA transcription of insulin-like growth factor I. Proc. Natl. Acad. Sci. U. S. A. 1992, 89:4874-4878.
140. Ulfarsson E., Karstrom A., Yin S., Girnita A., Vasilcanu D., Thoren M., Kratz G., Hillman J., Axelson M., Larsson O., Girnita L. Expression and growth dependency of the insulin-like growth factor I receptor in craniopharyngioma cells: a novel therapeutic approach. Clin. Cancer Res. 2005, 11:4674-4680.
141. Ullrich A., Schlessinger J. Signal transduction by receptors with tyrosine kinase activity. Cell 1990, 61:203-212.
142. Usui I., Imamura T., Satoh H., Huang J., Babendure J.L., Hupfeld C.J., Olefsky J.M. GRK2 is an endogenous protein inhibitor of the insulin signaling pathway for glucose transport stimulation. EMBO J. 2004, 23:2821-2829.
143. Vasilcanu D., Weng W.H., Girnita A., Lui W.O., Vasilcanu R., Axelson M., Larsson O., Larsson C., Girnita L. The insulin-like growth factor-1 receptor inhibitor PPP produces only very limited resistance in tumor cells exposed to long-term selection. Oncogene 2006, 25:3186-3195.
144. Vasilcanu R., Vasilcanu D., Sehat B., Yin S., Girnita A., Axelson M., Girnita L. Insulin-like growth factor type-I receptor-dependent phosphorylation of extracellular signal-regulated kinase 1/2 but not Akt (protein kinase B) can be induced by picropodophyllin. Mol. Pharmacol. 2008, 73:930-939.
145. Violin J.D., Lefkowitz R.J. Beta-arrestin-biased ligands at seven-transmembrane receptors. Trends Pharmacol. Sci. 2007, 28:416-422.
146. Vitale M., Prestat G., Lopes D., Madec D., Kammerer C., Poli G., Girnita L. New picropodophyllin analogs via palladium-catalyzed allylic alkylation-Hiyama cross-coupling sequences. J. Org. Chem. 2008, 73:5795-5805.
147. Wang M., Xie Y., Girnita L., Nilsson G., Dricu A., Wejde J., Larsson O. Regulatory role of mevalonate and N-linked glycosylation in proliferation and expression of the EWS/FLI-1 fusion protein in Ewing's sarcoma cells. Exp. Cell Res. 1999, 246:38-46.
148. Wang Y., Hailey J., Williams D., Wang Y.L., Lipari P., Malkowski M., Wang X.Y., Xie L., Li G.H., Saha D., Lam W., Ling W., Cannon-Carlson S., Greenberg R., Ramos R.A., Shields R., Presta L., Brams P., Bishop W.R., Pachter J.A. Inhibition of insulin-like growth factor-I receptor (IGF-IR) signaling and tumor cell growth by a fully human neutralizing anti-IGF-IR antibody. Mol. Cancer Ther. 2005, 4:1214-1221.
149. Waters C., Pyne S., Pyne N.J. The role of G-protein coupled receptors and associated proteins in receptor tyrosine kinase signal transduction. Semin. Cell Dev. Biol. 2004, 15:309-323.
150. Whalen E.J., Rajagopal S., Lefkowitz R.J. Therapeutic potential of beta-arrestin- and G protein-biased agonists. Trends Mol. Med. 2011, 17:126-139.
151. Whalen E.J., Rajagopal S., Lefkowitz R.J. Therapeutic potential of β-arrestin- and G protein-biased agonists. Trends Mol. Med. 2011, 17:126-139.
152. Wisler J.W., Xiao K., Thomsen A.R., Lefkowitz R.J. Recent developments in biased agonism. Curr. Opin. Cell Biol. 2014, 27:18-24.
153. Wyatt D., Malik R., Vesecky A.C., Marchese A. Small ubiquitin-like modifier modification of arrestin-3 regulates receptor trafficking. J. Biol. Chem. 2011, 286:3884-3893.
154. Yee D. Insulin-like growth factor receptor inhibitors: baby or the bathwater?. J. Natl. Cancer Inst. 2012, 104:975-981.
155. Yin S., Girnita A., Stromberg T., Khan Z., Andersson S., Zheng H., Ericsson C., Axelson M., Nister M., Larsson O., Ekstrom T.J., Girnita L. Targeting the insulin-like growth factor-1 receptor by picropodophyllin as a treatment option for glioblastoma. Neuro Oncol. 2010, 12:19-27.
156. Zhang M., Liu X., Zhang Y., Zhao J. Loss of betaarrestin1 and betaarrestin2 contributes to pulmonary hypoplasia and neonatal lethality in mice. Dev. Biol. 2010, 339:407-417.
157. Zheng H., Shen H., Oprea I., Worrall C., Stefanescu R., Girnita A., Girnita L. beta-Arrestin-biased agonism as the central mechanism of action for insulin-like growth factor 1 receptor-targeting antibodies in Ewing's sarcoma. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:20620-20625.
158. Zheng H., Worrall C., Shen H., Issad T., Seregard S., Girnita A., Girnita L. Selective recruitment of G protein-coupled receptor kinases (GRKs) controls signaling of the insulin-like growth factor 1 receptor. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:7055-7060.